Publicacions en col·laboració amb investigadors/es de Hospital Clínico San Carlos de Madrid (145)

2024

  1. A specific natural killer cells phenotypic signature associated to long term elite control of HIV infection

    Journal of Medical Virology, Vol. 96, Núm. 5

  2. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  3. Incidence of sexually transmitted infections and screening models among pre-exposure prophylaxis users

    Enfermedades Infecciosas y Microbiologia Clinica

  4. Monkeypox virus genomic accordion strategies

    Nature Communications, Vol. 15, Núm. 1

  5. Mpox, herpes, and enteroviruses: Differential diagnosis

    Journal of Medical Virology

  6. Pre-exposure prophylaxis program in the Community of Madrid: Two years of experience

    Enfermedades Infecciosas y Microbiologia Clinica

  7. Subclinical atherosclerosis burden in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors

    BMC Infectious Diseases, Vol. 24, Núm. 1

  8. T Cell Homeostasis Disturbances in a Cohort of Long-Term Elite Controllers of HIV Infection

    International Journal of Molecular Sciences, Vol. 25, Núm. 11

2023

  1. Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19

    Infectious Diseases Now, Vol. 53, Núm. 7

  2. Differences in the inflammatory response among hospitalized patients with distinct variants of SARS-CoV-2

    Frontiers in Immunology, Vol. 14

  3. Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study

    The Lancet Microbe, Vol. 4, Núm. 1, pp. e21-e28

  4. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  5. Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  6. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors

    Biomedicines, Vol. 11, Núm. 4

  7. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701

  8. TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

    Thorax, Vol. 78, Núm. 8, pp. 816-824

  9. Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125

  10. Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry

    International Journal of Clinical Practice, Vol. 2022

  2. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

    Open Forum Infectious Diseases